Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Stevanato will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Jazz doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. ...